BRPI0211844B8 - composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica - Google Patents

composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica

Info

Publication number
BRPI0211844B8
BRPI0211844B8 BR0211844A BR0211844A BRPI0211844B8 BR PI0211844 B8 BRPI0211844 B8 BR PI0211844B8 BR 0211844 A BR0211844 A BR 0211844A BR 0211844 A BR0211844 A BR 0211844A BR PI0211844 B8 BRPI0211844 B8 BR PI0211844B8
Authority
BR
Brazil
Prior art keywords
compound
alkyl
phenoxy
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Application number
BR0211844A
Other languages
English (en)
Other versions
BR0211844A (pt
BRPI0211844B1 (pt
Inventor
Masui Seiichiro
Sakuma Shogo
Kanda Takashi
Yamakawa Tomio
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Publication of BR0211844A publication Critical patent/BR0211844A/pt
Publication of BRPI0211844B1 publication Critical patent/BRPI0211844B1/pt
Publication of BRPI0211844B8 publication Critical patent/BRPI0211844B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Abstract

"composto e ativador de receptor delta ativado por proliferador de peroxissoma". um composto representado pela seguinte fórmula geral (i): (em que r^ 1^ representa fenila, etc, que pode ter substituintes selecionado dentre o grupo consistindo de alquila c~ 1-8~ alquila c~ 1-8~ tendo halogênio, halogênio, hidroxila, etc., r^ 2^ representa alquila c~ 1-8~, etc.; a representa oxigênio, enxofre, etc;, x representa cadeia alquileno c~ 1-8~, etc; y representa c(=o), ch=ch, etc.; r^ 3^, r^ 4^, e r^ 5^ cada representa hidrogênio, alquila c~ 1-8~, etc; b representa ch ou nitrogênio; z representa oxigênio ou enxofre; r^ 6^ e r^ 7^ representa, cada, hidrogênio, alquila c~ 1-8~, etc.; e r^ 8^ representa hidrogênio ou alquila c~ 1-8~, desde que pelo menos um dentre r^ 3^, r^ 4^ e r^ 5^ não é hidrogênio) ou um sal do composto; e um ativador de ppar-<sym> que contém o composto ou sal como o ingrediente ativo.
BR0211844A 2001-08-10 2002-08-02 composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica BRPI0211844B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001243734 2001-08-10
PCT/JP2002/007897 WO2003016291A1 (fr) 2001-08-10 2002-08-02 Activateur du recepteur $g(d) sensible au proliferateur de peroxysome

Publications (3)

Publication Number Publication Date
BR0211844A BR0211844A (pt) 2004-08-31
BRPI0211844B1 BRPI0211844B1 (pt) 2019-08-27
BRPI0211844B8 true BRPI0211844B8 (pt) 2021-05-25

Family

ID=19073779

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211844A BRPI0211844B8 (pt) 2001-08-10 2002-08-02 composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica

Country Status (16)

Country Link
US (3) US7265137B2 (pt)
EP (1) EP1424330B1 (pt)
JP (3) JP4421895B2 (pt)
KR (1) KR100901683B1 (pt)
CN (1) CN1330641C (pt)
AT (1) ATE526319T1 (pt)
AU (1) AU2002323776B2 (pt)
BR (1) BRPI0211844B8 (pt)
CA (1) CA2457054C (pt)
CY (1) CY1112130T1 (pt)
DK (1) DK1424330T3 (pt)
ES (1) ES2372813T3 (pt)
IL (2) IL160304A0 (pt)
MX (1) MXPA04001258A (pt)
PT (1) PT1424330E (pt)
WO (1) WO2003016291A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
EP1424330B1 (en) 2001-08-10 2011-09-28 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-responsive receptor delta
DE60232739D1 (de) * 2001-10-12 2009-08-06 Nippon Chemiphar Co Aktivator des peroxisomproliferator-aktivierten rezeptors delta
EP1637161A4 (en) * 2003-04-22 2007-06-27 Astellas Pharma Inc MEANS FOR THE TREATMENT OF NEURODEGENERATIVE ILLNESSES OF THE BRAIN WITH PPAR [delta] AGONIST
NZ545943A (en) 2003-09-19 2009-09-25 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US20050203151A1 (en) * 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
US7554974B2 (en) * 2004-03-09 2009-06-30 Tekelec Systems and methods of performing stateful signaling transactions in a distributed processing environment
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
ATE515494T1 (de) 2004-05-05 2011-07-15 High Point Pharmaceuticals Llc Neue verbindungen, deren herstellung und verwendung
WO2005105726A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
WO2006041197A1 (ja) * 2004-10-14 2006-04-20 Nippon Chemiphar Co., Ltd. ペルオキシソーム増殖剤活性化受容体δの活性化剤
RU2007135745A (ru) * 2005-02-28 2009-04-10 Ниппон Кемифар Ко., Лтд. (JP) АКТИВАТОР δ- РЕЦЕПТОРА, АКТИВИРУЕМОГО ПРОЛИФЕРАТОРОМ ПЕРОКСИСОМЫ
US20090203908A1 (en) * 2005-05-25 2009-08-13 Nippon Chemiphar Co., Ltd. Activator for Peroxisome Proliferator-Activated Receptor
MX2007016374A (es) 2005-06-30 2008-03-05 Novo Nordisk As Acidos fenoxiaceticos como activadores ppar delta.
AU2006287521A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. PPARactive compounds
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
CN101272784A (zh) 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途
BRPI0616465A2 (pt) * 2005-09-29 2011-06-21 Sanofi Aventis derivados de fenil-[1,2,4]-oxadiazol-5-ona com grupo fenila, bem como seu uso, composição farmacêutica compreendo os mesmos e processo de preparação da referida composição farmacêutica
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
JP2009529512A (ja) 2006-03-09 2009-08-20 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 新規な化合物、それらの製造法、及び使用法
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
AU2013202514B2 (en) * 2006-04-18 2015-09-17 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor delta
RU2435764C2 (ru) * 2006-04-18 2011-12-10 Ниппон Кемифар Ко., Лтд. АГЕНТ, АКТИВИРУЮЩИЙ РЕЦЕПТОР, АКТИВИРУЕМЫЙ ПРОЛИФЕРАТОРАМИ ПЕРОКСИСОМ δ
WO2007122970A1 (ja) * 2006-04-20 2007-11-01 Osaka University 核内受容体に結合するリガンド
AU2007309570B2 (en) 2006-10-20 2012-07-12 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
JP2010506916A (ja) 2006-10-20 2010-03-04 メルク エンド カムパニー インコーポレーテッド ボンベシンレセプターサブタイプ３モジュレーターとしての置換イミダゾール
CA2667003A1 (en) 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
FR2910893A1 (fr) * 2006-12-29 2008-07-04 Genfit Sa Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazolyl)-phenyl-propan-1-one substitues, preparations et utilisations.
BRPI0811612A2 (pt) * 2007-05-21 2014-11-11 Senju Pharma Co Composições farmacêuticas que contêm agonista ppardelta
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
CA2708391A1 (en) * 2007-12-13 2009-06-25 Sri International Ppar-delta ligands and methods of their use
US8648208B2 (en) * 2008-04-15 2014-02-11 Nippon Chemiphar Co. Ltd. Activating agent for peroxisome proliferator activated receptor
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5357894B2 (ja) * 2008-12-01 2013-12-04 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体およびその医薬用途
JP2012116753A (ja) * 2009-03-26 2012-06-21 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤活性化受容体の活性化剤
AU2010282399A1 (en) 2009-08-14 2012-03-01 Cerenis Therapeutics Holding S.A. Use of PPAR delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases
EP2538784B1 (en) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazole derivatives useful anti-diabetic agents
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
CN104994848A (zh) 2013-02-22 2015-10-21 默沙东公司 抗糖尿病二环化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP3043789B1 (en) 2013-09-09 2020-07-08 vTv Therapeutics LLC Use of a ppar-delta agonists for treating muscle atrophy
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN105237487B (zh) * 2015-10-19 2017-10-10 安徽中医药大学 含川芎嗪基查尔酮芳氧烷酸类化合物、制备方法及其应用
JPWO2017195875A1 (ja) * 2016-05-12 2019-03-22 日本ケミファ株式会社 創傷治療剤
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
CA2090283A1 (en) * 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
JP3722855B2 (ja) * 1993-09-14 2005-11-30 武田薬品工業株式会社 ２，４−オキサゾリジンジオン誘導体およびそれを含んでなる医薬
GB9426448D0 (en) 1994-12-30 1995-03-01 Wellcome Found Process
KR100436812B1 (ko) * 1995-01-06 2004-08-31 도레이 가부시끼가이샤 벤젠축합헤테로환유도체및그유도체를유효성분으로함유하는의약조성물
CA2171702A1 (en) * 1995-03-14 1996-09-15 Takashi Sohda Benzofuran compounds and their use
WO1996035688A1 (fr) 1995-05-08 1996-11-14 Nippon Chemiphar Co., Ltd. Derives de 2,4-thiazolidinedione ou d'oxazolidinedione et agent hypoglycemique
CN1209809A (zh) 1996-01-22 1999-03-03 藤泽药品工业株式会社 新化合物
WO1997028115A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Antidiabetic agents
US20020032330A1 (en) * 1996-12-24 2002-03-14 Yutaka Nomura Propionic acid derivatives
ES2320181T3 (es) * 1997-07-24 2009-05-19 Astellas Pharma Inc. Composiciones farmaceuticas que tienen un efecto reductor del colesterol.
US6589969B1 (en) * 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
ES2204684T3 (es) * 1999-08-27 2004-05-01 Eli Lilly And Company Derivados de biaril-oxa(tia)zol y su uso como modulares de ppar.
TW200514783A (en) * 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PE20011010A1 (es) 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
JP2001354671A (ja) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
WO2002014291A1 (en) * 2000-08-11 2002-02-21 Nippon Chemiphar Co.,Ltd. PPARδ ACTIVATORS
GB0031109D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
JP4157381B2 (ja) * 2001-03-23 2008-10-01 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体の活性化剤
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
EP1424330B1 (en) 2001-08-10 2011-09-28 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-responsive receptor delta

Also Published As

Publication number Publication date
KR20040023741A (ko) 2004-03-18
DK1424330T3 (da) 2012-01-16
JP2009102442A (ja) 2009-05-14
WO2003016291A1 (fr) 2003-02-27
CY1112130T1 (el) 2015-11-04
US7648999B2 (en) 2010-01-19
BR0211844A (pt) 2004-08-31
JPWO2003016291A1 (ja) 2004-12-02
MXPA04001258A (es) 2005-06-06
US20080009631A1 (en) 2008-01-10
US7265137B2 (en) 2007-09-04
BRPI0211844B1 (pt) 2019-08-27
JP4421895B2 (ja) 2010-02-24
US20050054674A1 (en) 2005-03-10
US7652045B2 (en) 2010-01-26
ES2372813T3 (es) 2012-01-26
CN1330641C (zh) 2007-08-08
CA2457054A1 (en) 2003-02-27
JP2009280622A (ja) 2009-12-03
JP5097180B2 (ja) 2012-12-12
EP1424330A4 (en) 2004-10-27
US20080009525A1 (en) 2008-01-10
AU2002323776B2 (en) 2008-07-31
KR100901683B1 (ko) 2009-06-08
EP1424330A1 (en) 2004-06-02
CA2457054C (en) 2011-10-11
IL160304A0 (en) 2004-07-25
CN1568316A (zh) 2005-01-19
IL160304A (en) 2010-12-30
EP1424330B1 (en) 2011-09-28
ATE526319T1 (de) 2011-10-15
PT1424330E (pt) 2011-12-22

Similar Documents

Publication Publication Date Title
BRPI0211844B8 (pt) composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica
DE60232739D1 (de) Aktivator des peroxisomproliferator-aktivierten rezeptors delta
DE60315265D1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
NO306720B1 (no) Sykliske ureaer og analoger som er anvendbare som retrovirale proteaseinhibitorer, farmasöytiske preparater omfattende disse og anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
PT976748E (pt) Derivados de pirrolidina com actividade inibidora de fosfolipase a2
GR3006746T3 (pt)
ATE380172T1 (de) Benzylaminanalogen
ATE374750T1 (de) Serotoninwiederaufnahme-inhibitoren
DK0962457T3 (da) Piperidoner som tachykininantagonister
MX9206930A (es) Nuevos compuestos
BR0109573A (pt) Composto ou uma pró-droga ou um sal farmacologicamente aceitável do mesmo, agente, composição farmacêutica, e, uso de um composto ou uma pró-droga ou um sal farmacologicamente aceitável do mesmo
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие
ATE192141T1 (de) Aromatische hydroxamsäure-verbindungen, ihre herstellung und verwendung
EA200000374A2 (ru) Новые соединения 2,3-метаноаминокислоты, способ их получения и содержащие их фармацевтические композиции
EA200000116A1 (ru) Противогрибковые соединения на основе 2,4,4-тризамещенных-1,3-диоксоланов
DE60238847D1 (de) Pyrimidinderivate enthaltendes medikament
MY101628A (en) Sulfonamide compounds and salts thereof, herbicidal compositions containing them, and process for producing them.
EA200200462A1 (ru) Производные 2-арилхинолина, их получение и терапевтическое применение
NO20010244D0 (no) Medikamenter inneholdende polyhydroksyalkylpyrazinderivater, deres fremstilling samt medikamenter inneholdende derivatene
TH65076A (th) สารประกอบดีเฮโลจิโน
DE69407227D1 (de) Die Verwendung von 2-Phenylmethylene-1-3&#39;-(amino)-2-(hydroxy)-propoxy-imino-cyclohexane-Derivaten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/08/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2681 DE 24-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.